News Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Welcomes Clint Burrus as Vice President, Customer Development

CHAPEL HILL, N.C., Aug 16, 2011 (BUSINESS WIRE) --

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, today announced the appointment of Clint Burrus, as Vice President, Customer Development. In this role, Mr. Burrus will be responsible for developing and executing managed markets, trade and reimbursement strategies for POZEN, starting with the Company's leading pipeline candidate PA32540. This novel, patented oral product is a coordinated-delivery tablet of enteric-coated aspirin and immediate-release omeprazole and is currently in Phase 3 clinical development in the United States with New Drug Application (NDA) submission scheduled for 2012. PA32540 is the first of a portfolio of integrated therapies designed to enable the full power of aspirin by reducing the gastrointestinal damage it causes. It is being investigated for the secondary prevention of cardiovascular disease in patients at risk for gastric-ulcers.

"Mr. Burrus is an exciting addition to the POZEN team," said Liz Cermak, Executive Vice President and Chief Commercial Officer of POZEN. "His extensive experience with managed markets, government, and trade customers will help us develop strategies in these areas that are critical to the success of the PA family of product candidates."

Prior to joining POZEN, Burrus held the position of Executive Vice President Managed Markets, Government, Trade and Public Policy, at King Pharmaceuticals, chairing King's Pricing Committee and Inventory Management Committee. Burrus served on the Board of Trustees for the Healthcare Institute of New Jersey, the Board of Directors for the National Association of Manufacturers and Board of Managers for Together RxAccess, a program that allows uninsured Americans access to immediate savings on prescription medications.


POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit

About PA

POZEN is creating a portfolio of integrated aspirin therapies - the PA product platform. The products in the PA portfolio are intended to significantly reduce gastric ulcers compared to taking aspirin alone.

The first candidate is PA32540. It is a coordinated-delivery tablet combining immediate release omeprazole, a proton pump inhibitor (PPI), layered around an aspirin core with a pH-sensitive coat. This novel, patented product is administered orally once a day and is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. POZEN has completed enrollment for the long-term safety study and the two pivotal studies, and is targeting a New Drug Application (NDA) filing in the second half of 2012.

Additionally, POZEN is conducting exploratory work on integrated aspirin therapies for other pain and pain-related conditions.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on GlaxoSmithKline for the sales and marketing of Treximet(R) and our dependence on AstraZeneca for the sales and marketing of VIMOVO(TM); competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended June 30, 2011.We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


Bill Hodges, Chief Financial Officer
Stephanie Bonestell
Manager, Investor Relations & Public Relations

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.